Liang Zhang

Liang Zhang, Ph.D.

Professor

Department of biopharmaceutical sciences

Email: zliang@suda.edu.cn

Biosketch

q  Education

2000.9.-2005.6.  The School of Bioscience and Biotechnology, China Pharmaceutical University (Ph.D.)

1992.9.-1996.6.  The department of Biopharmaceutical Analysis, China Pharmaceutical University (Bachelor)

q  Work experience

2016.7.-present The department of Biopharmaceutical Sciences, Soochow University (Professor)

2014.8.-2015.8. The department of Immunity, Mayo Clinic, USA (Visiting Scholar)

2008.7.-2016.67. The department of Biopharmaceutical Sciences, Soochow University (Associate Professor)

2007.9.-2011.9. The Institute of Medical Biology, Soochow University, China (Postdoctor)

2005.8.-2008.6. The department of Biopharmaceutical Sciences, Soochow University (Lecturer)

Research Interests

q  Tumor Immunity : major in the study of immune checkpoints

q  Immunotherapy

q  Signaling transduction controlling tumor growth

q  Ubiquitination mechanism of immune checkpoints

Research Fund

q  National Nature Science Foundation of China(No. 82273945) :The deubiquitinase USP2a regulates B7-H4 stability and tumor immune evasion 

q  The grant of immunotherapy of lung cancer: The study of immune checkpoint B7-H4 in promoting tumor immune evasion of lung adenocarcinoma

q  National Nature Science Foundation of China(No. 31370872) : The nuclear localization of B7-H4 contributes to tumor proliferation

Select Publications

1、Lu Y, Wu F, Cao Q, Sun Y, Huang M, Xiao J, Zhou B, Zhang L. B7-H4 is increased in lung adenocarcinoma harboring EGFR-activating mutations and contributes to immunosuppression. Oncogene, 2022, 41(5):704-717. （Corresponding author）

2、 Zhao Z.,Zhang N., Li A.,Zhou B., Chen Y, Chen S., Huang M.,Wu F., Zhang L. Insulin-like growth factor-1 receptor induces immunosuppression in lung cancer by upregulating B7-H4 expression through the MEK/ERK signaling pathway. Cancer Letters, 2020,485:14-26. （Corresponding author）

3、Zhou B, Lu Y, Zhao Z, Shi T, Wu H, Chen W, Zhang L, Zhang X. B7-H4 expression is upregulated by PKCδactivation and contributes to PKCδ-induced cell motility in colorectal cancer. Cancer Cell International, 2022, 22(1):147. （Corresponding author）

4、L Zhang, H Wu, D Lu, G Li, C Sun, H Song, et al. The costimulatory molecule B7-H4 promote tumor progression and cell proliferation through translocating into nucleus. Oncogene, 2013, 32(46):5347-5358. (First author)

5、Xu R, Zeng S, Xie W, Sun C, Chen YL, Chen MJ, Zhang L. The expression and function of Frizzled-7 in human renal cell carcinoma. Clinical and Translational Oncology, 2016, 18(3): 269-76. （Corresponding author）

6、Zeng S, Song H, Chen Y, Xie W, Zhang L. B7-H4-mediated immunoresistance is suppressed by PI3K/Akt/mTOR pathway inhibitors. Moleuclar Biology, 2016, 50(6):887-894. （Corresponding author）

7、Li A, Zhang N, Zhao Z, Chen Y, Zhang L. Overexpression of B7-H4 promotes renal cell carcinoma progression by recruiting tumor-associated neutrophils via upregulation of CXCL8. Oncology Letters, 2020, 20(2):1535-1544. （Corresponding author）

8、Chuangyang Sun, Hui Song, Hua Zhang, Chuansheng Hou, Tianhang Zhai, Lv Huang, Liang Zhang. CD133 expression in renal cell carcinoma (RCC) is correlated with nuclear hypoxia-inducing factor 1α(HIF-1α). Journal of Cancer Research and Clinical Oncology, 2012 138(10):1619-1624. （Corresponding author）

9、Yong-Yan Bei, Xiao-Feng Zhou, Ben-Gang You, Zhi-Qiang Yuan, Wei-Liang Chen, Peng Xia, Yang Liu, Yong Jin, Xio-Juan Hu, Qiao-Ling Zhum Chun-Ge Zhang, Xue-Nong Zhang, Liang Zhang. Application of the central composite design to optimize the preparation of novel micelles of harmine. International Journal of Nanomedicine, 2013,8: 1795-1808. （Corresponding author）

10、Chuan Y Sun, Ya C Zang, Yu X San, Wei Sun, Liang Zhang. Proteomic analysis of clear cell renal cell carcinoma. Saudi Med J, 2010, 31(5):525-532. （Corresponding author）

11、Yong-Yan Bei, Zhi-Qiang Yuan, Liang Zhang, et al. Novel self-assembled micelles based on palmitoyl-trimethyl-chitosan for efficient delivery of harmine to liver cancer. Expert Opinion on Drug Delivery, 2014,11(6):843-854. (Co-first author)